Down-regulated HHLA2 enhances neoadjuvant immunotherapy efficacy in patients with non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD)

Down-regulated HHLA2 enhances neoadjuvant immunotherapy efficacy in patients with non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD)

Abstract Background Emerging data suggested a favorable outcome in advanced non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD) patients treated by immunotherapy. The objective of this study was to investigate the effectiveness of neoadjuvant immunotherapy among NSCL...

Full description

Bibliographic Details
Main Authors: Ao Zeng, Yanze Yin, Zhilong Xu, Abudumijiti Abuduwayiti, Fujun Yang, Mohammed Saud Shaik, Chao Wang, Keyi Chen, Xinyun Fang, Jie Dai
Format: Article
Language:English
Published: BMC 2024-03-01
Series:BMC Cancer
Subjects:
Non-small cell lung cancer
Chronic obstructive pulmonary disease
Neoadjuvant immunotherapy
HERV–H LTR-associating protein 2
Tissue-resident memory T cells
Online Access:https://doi.org/10.1186/s12885-024-12137-5

Internet

https://doi.org/10.1186/s12885-024-12137-5

Similar Items